Obstructive sleep apnea (OSA) is characterized by repeated episodes of upper airway obstruction, resulting in hypoxemia, hypercapnia and sleep fragmentation. Pathophysiological sequelae include sympathetic activation, increased oxidative stress and a generalized inflammatory response, culminating in endothelial dysfunction. These are the proposed mechanisms that mediate the increased risk of hypertension and cardiovascular disease among patients with OSA outside of pregnancy. It is intriguing to consider the consequences of these events on pregnancy outcomes. There is a growing literature on the impact of maternal OSA on hypertensive disorders of pregnancy, gestational diabetes and impaired fetal growth. The data, while promising, require confirmation with larger numbers to verify the findings. OSA may be an important mediator of the poor perinatal outcomes associated with maternal obesity; moreover, one which may be amenable to treatment. This review discusses OSA and summarizes the current literature linking OSA with adverse perinatal outcomes.
Introduction
Obstructive sleep apnea (OSA) is characterized by repeated periods of complete or partial upper airway collapse with consequent hypoxemia and hypercarbia. These episodes of hypoxemia result in frequent arousals, and thus sleep fragmentation. The repeated episodes of hypoxia and reoxygenation are also associated with significant endocrine and metabolic disturbance, which are responsible for the increase in hypertension, metabolic syndrome and cardiovascular risk observed among patients with OSA. The potential impact of OSA on population health is likely to become more important, given that the incidence of OSA is increasing, in parallel with the epidemic of obesity. Obesity in pregnancy is associated with an increased risk of adverse pregnancy outcomes, and it is therefore important to consider whether OSA may be an important contributor. While the data remain scant, there is a growing literature on the impact of OSA on important perinatal outcomes, such as hypertensive disorders of pregnancy, gestational diabetes and fetal compromise.
Sleep-disordered breathing and OSA Sleep-disordered breathing (SDB) is a descriptive term for the spectrum of disorders characterized by upper airway resistance during sleep. SDB ranges in severity from snoring, its mildest form, through to the most severe form in OSA syndrome. 1 In OSA, repeated episodes of partial or complete upper airway collapse lead to apneas (cessation of airflow X10 s) or hypopneas (discernible reduction in airflow X10 s associated with either an oxyhemoglobin desaturation or an arousal, detected by electroencephalography). 2, 3 These episodes occur most commonly at sleep onset and during periods of rapid eye movement sleep.
Diagnosis of OSA
Clinically, patients with OSA present with the characteristic history of habitual snoring, witnessed apneas and excessive daytime sleepiness, resulting from frequent arousal and sleep fragmentation. There are gender-specific variations in the presentation of OSA. Women tend to report less snoring or choking, but more daytime somnolence, headaches and poorer sleep quality. 4, 5 Women also have more rapid eye movement-related apneas (but less non-rapid eye movement apneas) than men. 6 A clinical suspicion of OSA may be supported by administration of screening questionnaires 7, 8 that combine clinical characteristics such as body mass index (BMI), and neck circumference with symptoms of SDB such as snoring, gasping, choking and daytime somnolence. These questionnaires have relatively poor sensitivity (62 to 69%) and specificity (23 to 56%), 9 and the predictive value of these questionnaires appears poorer in women than in men. and oxygen saturation, and is necessary to confirm the diagnosis and determine the severity of the disease.
1,2 Disease severity is most commonly classified using the apnea-hypopnea index (AHI). The AHI is the number of apneas or hypopneas recorded per hour of sleep. Mild OSA is defined as an AHI of 5 to 15, moderate disease an AHI of 15 to 30 and severe disease an AHI of >30. 1 Epidemiology of OSA Obesity is a significant risk factor for OSA. 4, 12, 13 Male gender is also associated with OSA, with population studies suggesting that OSA is two to three times more common among males than females, 4,12 even after adjusting for BMI. The reason for this gender difference, whether anatomical or endocrine in origin, remains elusive. OSA prevalence appears to increase with age in midlife in both men and women, but plateaus around the age of 60 years. 12 The prevalence of OSA will vary according to the criteria used. The Wisconsin Sleep cohort studyFusing a definition of AHI X5 per hourFreported a prevalence of OSA among women aged 30 to 49 years of 7 to 9%. 4 More recently, the estimated prevalence of OSA in women was 2% and only 0.6% in premenopausal women, but this group used a higher cutoff for the diagnosis of OSA (AHIX10). 14 While cutoffs have been generated in the nonpregnant population on the basis of a stepwise increase in health risks, 15, 16 these diagnostic thresholds may need to be altered in pregnancy as more data emerge linking OSA criteria to relevant perinatal outcomes.
Consequences of OSA
The consequences of sleep fragmentation and excessive daytime sleepiness include an increased risk of traffic accidents and occupational injury, 17, 18 with the attendant financial burden related to reduced productivity and costs of disability. 19 The metabolic and endocrine sequelae of OSA contribute to the observed increase in cardiovascular morbidity, and are summarized below, and in Figure 1 .
Sympathetic/endocrine sequelae
Periods of hypoxia and hypercapnia in OSA result in sympathetic activation, with elevated catecholamines; 20, 21 baroreceptor sensitivity may also be altered, resulting in sustained hypertension. 22 Hypoxia and sleep fragmentation may increase cortisol secretion with abnormalities in insulin and glucose metabolism. This continued cortisol secretion reduces glucocorticoid receptor sensitivity, resulting in chronic hypothalamic-pituitaryadrenal axis activation. 23, 24 Inflammatory sequelae Recurrent episodes of hypoxia and reoxygenation activate neutrophils, which adhere to endothelium and generate reactive oxygen species. Endothelial dysfunction results, 25 and contributes to the development of atherosclerosis. 26 Increased proinflammatory cytokines (interleukin-6), tumor necrosis factor-a and C-reactive protein may contribute to atherosclerosis and endothelial dysfunction, insulin resistance
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Altered adipocytokines
Reduced adiponectin and leptin resistance and type 2 diabetes; 27, 28 OSA is associated with elevations in these inflammatory markers 29 and treatment with Continuous Positive Airway Pressure (CPAP) is associated with significant reduction in interleukin-6 and C-reactive protein. 27 
Impact on adipocytokines
Adipokines are hormones derived from adipose tissue, which regulate body metabolism and energy homeostasis. Leptin is responsible for negative energy balance, increasing energy expenditure and reducing food intake. 30 Leptin levels are increased in the obese, suggesting resistance to its metabolic effects. Leptin levels are positively correlated with AHI, 30 independent of BMI. 31 Leptin may predispose to platelet aggregation and has been implicated as an independent marker of cardiovascular risk. 32 Adiponectin is another adipokine with insulin-sensitizing, anti-atherogenic and anti-inflammatory properties. It is reduced by proinflammatory cytokines and the levels of this hormone are lower in patients with OSA. 33, 34 It is via these mechanisms that an increasing AHI is associated with a stepwise increase in the risk of hypertension, 16 myocardial infarction, 35 stroke, 16,35,36 diabetes 37 and metabolic syndrome.
38-40
These associations remain significant even after adjusting for the potential confounding effects of obesity. Given the extensive endocrine and metabolic disturbance accompanying OSA, it is worth considering whether these may have important maternal and fetal consequences in pregnancy.
Sleep-disordered breathing in pregnancy
When compared with the nonpregnant state, there are physical and endocrine alterations in pregnancy, which may both promote and protect against OSA; these are summarized in Table 1 . There is no consensus on the definition of OSA in pregnancy and, consequently, the prevalence is unknown. Most studies conclude that pregnancy increases the risk of snoring, although they are largely based on self-reported questionnaires and lack objective validation. 41, 46, 47 While self-reported snoring correlates modestly with PSG findings in the nonpregnant population, this relationship may be less robust in pregnancy. 10 Apnea symptoms increase through gestation, but do not reliably correlate with PSG findings. 48 Similarly, obesity does not seem to be as strongly associated with OSA in pregnancy as in the nonpregnant population. 41 Large longitudinal cohort studies using PSG are therefore needed to determine the prevalence, and severity, of OSA in the pregnant population.
Upper airways are significantly narrowed in late gestation compared with postpartum, 49 suggesting that the changes in pregnancy resolve post-delivery. 50 Symptoms of SDB (or even the confirmation of OSA with a sleep study) in pregnancy may thus be a 'transient' diagnosis without the same long-term health implications as chronic OSA. Nevertheless, it is important to consider whether SDB in pregnancy may have important shortterm perinatal consequences. The relationships that have received the most attention to date are those between SDB and the hypertensive disorders of pregnancy, gestational diabetes and fetal compromise.
Hypertensive disorders of pregnancy
The interaction between SDB and preeclampsia is complex. There are shared risk factors such as obesity and increasing maternal age, yet SDB may contribute to the development of preeclampsia via recurrent episodes of placental hypoxia, increased hypertension and by inducing endothelial dysfunction. The upper airway edema accompanying preeclampsia may, in turn, worsen symptoms of SDB. The interaction between SDB and preeclampsia is summarized in Figure 2 , and highlights the potential for OSA to contribute to disease development, modulation of the phenotype or disease amplification.
The evidence suggests that SDB is associated with an increased risk of hypertension in pregnancy. Preeclampsia has been reported to be significantly increased among snorers compared with non-snorers (10 versus 4%, P<0.05), as has gestational hypertension (14 versus 6%, P<0.01). 47 Snoring and 'excessive daytime sleepiness' are reported more commonly in later pregnancy in women with preeclampsia compared with those without preeclampsia or nonpregnant controls. 51 Perez-Chada et al. 52 and Bourjeily et al. 53 have both performed large cross-sectional studies immediately postpartum. Perez-Chada et al. 52 reported an increase in pregnancy-induced hypertension and preeclampsia among women with symptoms of SDB (odds ratio (OR) ¼ 1.8; 1.2 to 2.8 for pregnancy-induced hypertension and preeclampsia combined) even after adjusting for potential confounders such as BMI. 52 Similarly, Bourjeily et al. Objective documentation of SDB with PSG confirms these observations. In a recent retrospective study, Louis et al. 54 found that when women with proven OSA (AHIX5) were compared with obese and normal weight-matched controls, preeclampsia occurred in 19% of OSA women, 11% of obese women (P ¼ 0.15) and 7% of normal weight controls (P ¼ 0.02). The risk of preterm birth was increased among patients with OSA (OR ¼ 2.6; 1.02 to 6.6), mostly due to indicated preterm birth associated with preeclampsia. 54 Champagne et al. 55 reported an OR of 7.5 for an AHI >15 among women with gestational hypertension compared to gestation-matched controls, even after adjustment for age and BMI. In the largest study to date, Reid et al. 56 observed that women with gestational hypertension had a higher AHI than the healthy control group (AHI 3.1 versus 0.5, P ¼ 0.04). Finally, Olivarez et al. 57 has confirmed among non-obese women that OSA is a significant independent risk factor for preeclampsia (adjusted OR ¼ 6.6, P ¼ 0.04).
In summary, these studies indicate an association with SDB and hypertensive disorders of pregnancy. Further studies are required with objective confirmation of SDB, larger numbers and appropriate adjustment for confounding variables to clarify the strength of this relationship.
Gestational diabetes
In the nonpregnant population, the link between SDB and the development of diabetes or insulin resistance has been established, independent of other risk factors such as obesity. Cross-sectional studies have suggested that up to 40% of patients with OSA will develop diabetes, independent of BMI. 37 Proposed mechanisms for this association include activation of the sympathetic nervous system, systemic inflammation and alteration of adipocytokines. 3 It is therefore plausible that the presence of SDB in pregnancy may predispose to the development of gestational diabetes. The potential interaction between OSA and gestational diabetes is summarized in Figure 3 . Recent data are emerging to support this relationship. Bourjeily et al. 53 administered a questionnaire to women after delivery and found that symptoms of SDB were associated with a higher likelihood of gestational diabetes, after adjusting for age, BMI, diabetes and chronic hypertension (OR ¼ 2.1; 1.3 to 3.4). Qiu et al. 58 demonstrated an increased risk of gestational diabetes mellitus in snoring pregnant women, although this association was only observed among women who were also overweight. In the only prospective study to date, Reutrakul et al. 59 administered a SDB screening questionnaire at the time of glucose tolerance testing in 169 women at B28 weeks gestation. They found that women who reported shortened sleep, frequent snoring and had an increased risk of SDB on screening had an OR of 3 to 3.4 for gestational diabetes, even after adjusting for potential confounders such as age and BMI.
This early data suggest that OSA is associated with an increased risk of gestational diabetes, but further evidence is required. Larger studies, using polysomnographic evidence of OSA rather than questionnaires, and carefully adjusting for the potential confounding effects of obesity are needed.
Fetal compromise
The potential for fetal sequelae related to SDB in pregnancy has received little attention to date. Nevertheless, the association between obesity and poor perinatal outcome generally, 60, 61 and stillbirth in particular, 62 is receiving increasing attention. Potential contributors include the association of maternal obesity with hypertensive disorders and diabetes. Other suggested mechanisms include hyperlipidemia, which reduces prostacyclin secretion, resulting in enhanced vasoconstriction and platelet aggregation. 63 Obesity is associated with poorer detection of fetal movements and of fetal growth restriction and with higher rates of birth asphyxia. 64 It is also plausible that OSA, with the repeated episodes of hypoxia and hypercapnia, systemic inflammatory response and endothelial dysfunction may be an important intermediary. The potential interaction between OSA and acute or chronic fetal compromise is summarized in Figure 4 .
A small number of studies have examined the association between OSA and poor fetal outcomes, with contradictory results. While some studies, using the crude measure of snoring as a surrogate for SDB, found no association with birthweight or Apgar scores, 46 ,65 a retrospective cross-sectional study of 502 women by Franklin et al. 47 reported an increase in small-for gestational-age infant and low Apgars among women who snored (7.1 vs 2.6% in non-snorers, P<0.05). A retrospective cohort study of women with PSG-confirmed OSA also found no difference in small-for gestational-age babies among affected women compared with obese and non-obese controls. 54 However, BMI is a difficult confounder to address when examining birth weight and OSA, as increasing BMI will generally be associated with excessive fetal size. The number of women with a small-for gestational-age infant will thus be small, and studies prone to underpowering. Identification of 'failure to achieve growth potential' would be a preferable outcome to birthweight alone, either by use of customized growth charts or documentation of an impaired growth trajectory in late pregnancy.
Sahin et al. 66 attempted to correlate short-term effects of maternal hypoxia due to OSA on fetal physiology by performing simultaneous PSG and non-stress testing in pregnant women with proven OSA. They demonstrated fetal heart rate decelerations in three out of four women during maternal desaturations. However, they did not characterize the fetal heart rate decelerations, therefore limiting the ability to determine their significance. By contrast, Olivarez et al. 67 performed simultaneous PSG and at least 3 h of continuous fetal heart rate monitoring on 100 pregnant women, 19 with sleep apnea, and found no association between fetal heart rate abnormalities and OSA.
Overall, studies examining the relationship between OSA and in utero markers of fetal health and well-being are in their infancy. There is a paucity of strong evidence linking OSA with fetal outcomes, due to small numbers and the use of snoring, an imperfect surrogate, for the diagnosis of OSA. Nevertheless, this area warrants further investigation, particularly if OSA may be an important intermediary between obesity and adverse perinatal outcomes, and given the importance of intrauterine fetal health on perinatal and long-term health outcomes.
Treatment of OSA
If OSA is confirmed to significantly contribute to important pregnancy outcomes such as hypertensive disorders of pregnancy, gestational diabetes and impaired fetal growth, then the potential for treatment in pregnancy with CPAP becomes an exciting possibility. CPAP provides a pneumatic splint by delivering airway pressure above atmospheric pressure, in order to increase upper airway cross-sectional area and volume and to keep the upper airway open during sleep. 68 CPAP is the mainstay of treatment for moderate-to-severe OSA outside of pregnancy. 69 The impact of CPAP in improving health outcomes in these patients is summarized below.
CPAP for OSA in the nonpregnant population
In placebo-controlled studies, CPAP has been shown to reduce the AHI in the short term 70 and to reduce subjective sleepiness when assessed using sleep questionnaires. 71 Studies have shown an improved driving ability 72 and that CPAP can reduce the risk of road traffic accidents. 73 CPAP has been shown to reduce daytime sympathetic activity, 74 hypothalamic-pituitary-adrenal activity 23 and oxidative stress. 26 Studies also suggest a sustained reduction in inflammatory factors in patients with good compliance with CPAP. 28, 27 Blood pressure control in the short term appears improved, 71, 75, 76 although data on the long-term impact on hypertension is contradictory. [77] [78] [79] The impact of CPAP on glucose intolerance is conflicting, [80] [81] [82] [83] with a recent meta-analysis concluding that CPAP had no impact on glucose metabolism. 84 One study has reported a 45% decrease in the prevalence of metabolic syndrome. 82 Studies investigating the effect of good compliance with CPAP on leptin, 83, 85 and adiponectin levels are also inconsistent. 84, 86, 87 Taken collectively, the main benefits of CPAP are the reduction of sleep disturbance and daytime symptoms, as well a reduction in short-term blood pressure among those with or without hypertension. These changes are accompanied by a concomitant reduction in sympathetic, hypothalamic-pituitary-adrenal and inflammatory activity with compliant use of CPAP. However, the effect of CPAP on glucose metabolism remains to be determined. Larger studies are still required to confirm the long-term effects of CPAP on hypertension, and determine the effect, if any, on glucose metabolism. CPAP for OSA in the pregnant population Given the established benefits associated with CPAP, it is recommended that women with OSA who require treatment continue using CPAP during pregnancy. While no study has specifically investigated the safety of CPAP in pregnancy, small studies have suggested that nasal CPAP in pregnancy is safe and effective. Good patient compliance and improvements in OSA-related symptoms have been demonstrated in pregnant women, 88 although only 12 patients participated in this study. Long-term compliance in the general population is reported to be much lower at around 54%, 89 although compliance has been shown to be better in women compared with men. 90 The only pregnancy-specific condition for which the therapeutic benefit of CPAP has been examined is pregnancy-induced hypertension. Treatment with CPAP in an attempt to improve blood pressure control among women with SDB has been the subject of a few small and uncontrolled studies. One study performed PSG on 11 women with preeclampsia, none of whom had OSA, as defined by AHI >10. All 11 women were studied on two consecutive nights and received nasal CPAP on the second night. They demonstrated a significant reduction in mean nocturnal systolic (149 to 129 mm Hg, P<0.012) and diastolic (93 to 73 mm Hg, P<0.007) blood pressure with CPAP. 91 In a prospective study of CPAP 12 women with risk factors for preeclampsia, without a prior diagnosis of OSA, had PSG performed. Although none of the women had OSA (defined as AHI X5), treatment with CPAP was associated with some improvement in blood pressure control, as evidenced by a blood pressure below 140/90 without additional need for antihypertensive agents in pregnancy. 92 Subsequently, a randomized study of 16 women with hypertension in early pregnancy compared nasal CPAP (n ¼ 7) with no treatment (n ¼ 9). The control group showed a progressive increase in blood pressure, with escalating antihypertensive requirement, while the treatment group showed a significant decrease in blood pressure across gestation, with decreased antihypertensive dosage. 93 While none of the treatment group had polysomnographic OSA, as defined by AHI X5, all these studies highlight that clinically significant AHI thresholds may be substantially different in pregnancy, and that further studies are needed to correlate AHI thresholds to relevant perinatal outcomes.
Conclusion
In the nonpregnant population, definitions and cutoffs for OSA have been established. The important role of OSA in long-term health outcomes, such as traffic and occupational accidents, and the adverse effect on vascular risk is recognized. For some of these outcomes, treatment with CPAP has been demonstrated to be effective. In pregnancy, the data are more limited. Definitions based on clinically significant thresholds remain to be determined. The cardiovascular, endocrine, inflammatory and metabolic sequelae that accompany OSA may have important implications in pregnancy. Clinical studies to date suggest that OSA in pregnancy may be associated with important maternal and fetal outcomes, although adequately powered studies with appropriate adjusting for confounding variables are awaited. If these associations are confirmed, OSA may partly explain the observed increase in adverse perinatal outcomes among obese women. Although early data are encouraging, it remains to be determined whether treatment with CPAP may be able to ameliorate some of the maternal and perinatal morbidity and mortality associated with these conditions.
